Theranostics pave way for personalized medicines in Europe, says report

Theranostics is an emerging field in clinical diagnostics, focussing on developing specific analysis to predict the most suitable drug for a patient, along with assessing the efficacy of the drug, notes a new report from Frost & Sullivan. It uses molecular assays to determine the optimum dose of drugs for a patient, paving the way for personalized medicine.

Although significant awareness has been created about personalized medicine, its full potential is yet to be tapped. Factors such as cost and regulatory timelines are the key hurdles that need to be addressed at the moment.

The new analysis from Frost & Sullivan, Strategic Analysis of the European Markets for Theranostics, finds that theranostics plays a crucial role in every step of the drug development process, primarily in the form of biomarker discovery, target selection and validation of biomarkers. The key applications of theranostics are covered in the following disease areas: cancer, cardiovascular diseases and neuro disorders.